Your missing links are here (28 October 2019)

Some of the best stuff we picked up around the Internet

By: Rasmus Kragh Jakobsen - Oct. 28, 2019
News

Top picks

  • The new Prime Editing prototype gene editing method explained by Emma Yasinski at The Scientist. Combining CRISPR-Cas9 and base-editing David Liu and colleagues at the Broad Institute cuts only one strand of DNA to gain better precision and similar efficiency as CRISPR-Cas9 solo. Also here and here.
  • Russian ‘CRISPR-baby’ scientist has started work. David Cyranoski, Nature News, reports that biologist Denis Rebrikov's controversial 'CRISPR-baby' plans have taken a turn from making HIV resistant babies to repair the gene linked to deafness, called GJB2. And here. And meet a deaf woman who considers collaborating with Rebrikov to have hearing 'CRISPR-babies'.
  • Promising new gene therapy for Duchenne muscular dystrophy using dystrophin's distant cousin utrophin
  • Geneticists retract study suggesting the chinese 'CRISPR-babies' might die early
  • Dynamic genomes - feature on how genes are born de novo from barren stretches of the genome.

Visionaries

  • Bill Gates og NIH invests in CRISPR gene therapy for the poor
  • NIH director, Francis S. Collins, lays out inspirational vision for the future of medical science
  • Jennifer Doudna on the gene-editing revolution

Industry

Uh ah wow

  • Amazing scientific visualization - 3D digital video tour for learning about biology and medicine
  • More visuals - I just love Nikon’s Small World Competition 'showcasing the beauty and complexity of life as seen through the light microscope'. Image Credit: Teresa Zgoda & Teresa Kugler, winning entry Nikon Small World Competition 2019
  • Oh, finally there's the tiny Greta beetle, and the rat-mobile (VIDEO)

Tags

HashtagArticleHashtagMissing links

Missing Links: Your missing links are here (28 October 2019)
Missing Links: Your missing links are here (28 October 2019)
CLINICAL TRIALS
Systemic Lupus Erythematosus SLE, (NCT06255028)
Sponsors:
Century Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Chronic Granulomatous Disease, CGD, (NCT06325709)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06287099)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine